$30 Million In New Funding Signals Better Day to Cure Cancer for Incyclix | North Carolina Biotechnology Center

Newly minted RTP cancer therapeutics developer Incyclix Bio has just received $30 million in Series B financing.

Related Keywords

North Carolina ,United States ,University Of North Carolina ,Chapel Hill ,Research Triangle Park ,John Bisi ,Laura Rowley ,Fred Eshelman ,Patrick Roberts ,Sid Subramony ,Incyclix Bio ,Jay Strum ,Life Science Economic Development ,University Of North Carolina At Chapel Hill ,Carolina Biotechnology Center ,Arc Therapeutics ,Eshelman Ventures ,Boxer Capita ,Brooks Horwitz ,Cycline Overexpressed ,North Carolina Biotechnology Center ,